28 results
6-K
EX-99.4
IMCR
Immunocore Holdings plc
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
treated closer to home in community setting1 25% of patients are now 1L3 40% +40% of patient potential 1. Internal estimates based on KIMMTRAKConnect data … helpful. “ ” - Community Physician of estimated potential mUM* lives covered for KIMMTRAK to date with policy260%
Delivering KIMMTRAK to patients
6-K
EX-99.3
IMCR
Immunocore Holdings plc
10 May 23
Current report (foreign)
7:27am
) receiving KIMMTRAK. In addition, the majority of mUM patients in the U.S. were being treated with KIMMTRAK in the community setting.
In France … KIMMTRAK will provide for patients; the ability of KIMMTRAK Connect to facilitate patient access in the community setting; the expected submission
6-K
EX-99.1
IMCR
Immunocore Holdings plc
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
treatment available. I am thrilled at this turning point for the uveal melanoma community. We are hugely supportive of Immunocore, which has introduced
6-K
EX-99.4
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
discussions 1. Recovering Excessive Funds for Unused and Needless Drugs Act of 2021 or the REFUND Act 11 Growth US community expansion 1L KIMMTRAK 3-yrs OS data
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
and delivering transformative immunomodulating medicines
$238.7M FY23 net sales with 3 Additional Growth Opportunities US Community & global expansion
6-K
EX-99.3
vnx3aeayhfy9
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
flaps07emhs9qbbp1
5 Apr 24
Prospectus with selling stockholder info
4:34pm
10-K
6g1ryvf0jb
28 Feb 24
Annual report
7:33am
424B7
ypwdfj jc41o
5 May 22
Prospectus with selling stockholder info
12:00am
20-F
EX-2.4
inwwgjo9flbhp1
25 Mar 21
Annual report (foreign)
7:01am
424B7
b4t nqi13l7w11m
30 Sep 22
Prospectus with selling stockholder info
4:15pm
S-3ASR
q6l85nvde0ohh2oz
20 Mar 24
Automatic shelf registration
8:51pm
424B5
tqi7n
9 Sep 22
Prospectus supplement for primary offering
4:23pm
F-3ASR
5ryz9pq0v
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
DRS/A
yqm5zvkaag8 48zer
19 Nov 20
Draft registration statement (amended)
12:00am
20-F
hl9eps8g
25 Mar 21
Annual report (foreign)
7:01am
DRS
jblg6vph 6khhtp
17 Nov 20
Draft registration statement
12:00am
424B4
x5ib798 vwfp6muk
8 Feb 21
Prospectus supplement with pricing info
8:36am
10-Q
wsbdn2cpx um0ty
8 May 24
Quarterly report
7:00am